For millions of women, a medical diagnosis often feels like a label that defines their experience. For those living with a complex hormonal disorder affecting approximately 1 in 8 women globally, that label has long been “Polycystic Ovary Syndrome,” or PCOS. However, for decades, patients and clinicians have argued that the name was not only inaccurate but actively hindered the quality of care.
In a landmark shift aimed at correcting this medical misunderstanding, a global coalition of experts and patients has introduced a new name for the condition: Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change, detailed in a recent publication in The Lancet, seeks to pivot the medical conversation away from a localized focus on the ovaries and toward the systemic, endocrine-driven nature of the disorder.
Affecting more than 170 million women worldwide, PMOS is characterized by fluctuations in hormones that impact far more than reproductive health. The condition manifests in a diverse array of symptoms, including metabolic dysfunction, weight struggles, mental health challenges, and skin issues. By rebranding the disorder, health professionals hope to reduce the frequency of missed diagnoses and the inadequate treatment that often follows a narrow clinical focus.
As a physician, I have seen how terminology dictates treatment. When a condition is named after a specific organ—in this case, the ovaries—there is a natural clinical tendency to treat the organ rather than the system. The shift to PMOS acknowledges that while the ovaries are involved, the root of the issue is a polyendocrine and metabolic struggle that permeates the entire body.
The Myth of the “Cyst”
The most significant driver behind the name change is a scientific correction. For years, the term “polycystic” led many to believe that the condition was defined by the presence of abnormal cysts on the ovaries. However, recent research has clarified a critical point: there is actually no increase in abnormal cysts in women with this condition.
Professor Helena Teede, an endocrinologist at Monash Health and Director of Monash University’s Monash Centre for Health Research &. Implementation, led the renaming process. Teede, who has spent decades researching the condition, noted that the previous name reduced a complex, long-term endocrine disorder to a misunderstanding about ovarian anatomy.
“It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition,” Teede said. She emphasized that while international guidelines have improved over time, the name itself remained a barrier to recognition.
A 14-Year Global Collaboration
The transition to PMOS was not a sudden decision but the result of a 14-year journey of global collaboration. The process involved more than 50 patient and professional organizations, including the Endocrine Society, the International Androgen Excess and Polycystic Ovary Syndrome Society (AE-PCOS Society), and the UK-based charity Verity.
To ensure the new name reflected the reality of those living with the condition, the team gathered more than 22,000 survey responses and conducted multiple international workshops. This patient-centric approach was designed to ensure the name met several core principles: scientific accuracy, ease of communication, avoidance of stigma, and cultural appropriateness.
Professor Terhi Piltonen, an international co-lead from Oulu University and Oulu University Hospital in Finland, highlighted the importance of cultural sensitivity. In some regions, reproductive terms can carry heavy social stigmas that may discourage women from seeking care. The coalition worked to ensure the new terminology was internationally informed and would not inadvertently harm patients in diverse cultural contexts.
| Feature | Previous Framing (PCOS) | New Framing (PMOS) |
|---|---|---|
| Primary Focus | Ovarian anatomy (Cysts) | Systemic endocrine/metabolic health |
| Perceived Scope | Reproductive system | Weight, mental health, skin, and reproduction |
| Clinical Risk | Missed systemic diagnoses | Integrated, multidisciplinary care |
| Patient Identity | Defined by “cysts” | Recognized as a complex hormonal disorder |
Impact on Clinical Practice and Patient Advocacy
For patients, the change is about more than just semantics; it is about accountability. Lorna Berry, an Australian woman living with PMOS who contributed to the renaming process, described the shift as life-changing. “This is about my daughters, their daughters, and the countless women yet to be born,” Berry said, noting that women deserve equitable healthcare from the start.
Rachel Morman, Chair of Verity, noted that by leading with “hormones” and recognizing the “metabolic dimension,” the medical community is forced to take the condition as seriously as the long-term health risk it represents. When a condition is framed as metabolic, it naturally draws attention to risks like insulin resistance and type 2 diabetes, which are often overlooked when the focus remains solely on fertility or ovarian morphology.
The transition to the new name will not happen overnight. A three-year transition period is currently underway, supported by an international education campaign targeting health professionals, governments, and researchers. This window allows clinicians to update their practice and patients to familiarize themselves with the new terminology.
For those seeking more information or resources in multiple languages, the Monash Centre for Health Research and Implementation provides updated materials to support patients and providers during this shift.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a licensed healthcare provider for diagnosis and treatment of any health condition.
The final step in this global transition will be the full implementation of the name Polyendocrine Metabolic Ovarian Syndrome in the 2028 International Guideline update, which will formally codify the standard of care under the new nomenclature.
Do you or a loved one live with this condition? We invite you to share your thoughts on this name change in the comments below or share this article to help spread awareness.
